Aug 15 (Reuters) - Lykos Therapeutics will lay off 75% of its workforce, or about 100 employees, and founder Rick Doblin will leave the board, the company said on Thursday, days after the U.S. FDA ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The CEO of Lykos Therapeutics will step down after the ...

Among the 89 rejection letters the Food and Drug Administration released last week detailing safety and effectiveness issues that prevented drugs from being approved was one of particular interest to ...

The journal Psychopharmacology has retracted three research papers on MDMA-assisted therapy due to alleged unethical conduct at study site In 2015, an unlicensed therapist who was part of the trial ...

FDA independent advisors have comprehensively voted against the use of Lykos Therapeutics’ therapy for post-traumatic stress disorder (PTSD) based on MDMA, also known as ecstasy, in a setback for the ...

MAPS Public Benefit Corp. said Friday it raised $100 million in an oversubscribed Series A round of financing as it works to win approval from the U.S. Food and Drug Administration to become the first ...

Lykos Therapeutics is restructuring after the FDA denied approval for MDMA-AT, reducing its workforce by 75% to focus on clinical development and FDA engagement. The FDA requested a third phase 3 ...

SAN JOSE, Calif., Aug. 9, 2024 /PRNewswire/ -- Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, announced that the U.S. Food and Drug Administration ("FDA") has ...